Tharimmune (NASDAQ:THAR) Trading Up 3.8% – Time to Buy?

Shares of Tharimmune, Inc. (NASDAQ:THAR) shot up 3.8% during mid-day trading on Monday . The company traded as high as $4.88 and last traded at $4.68. 798,582 shares traded hands during trading, a decline of 46% from the average session volume of 1,476,877 shares. The stock had previously closed at $4.51.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Tharimmune in a research note on Monday, December 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Tharimmune currently has an average rating of “Sell”.

Tharimmune Stock Performance

The business’s 50-day moving average is $3.52 and its two-hundred day moving average is $3.25. The firm has a market capitalization of $176.58 million, a price-to-earnings ratio of -1.17 and a beta of 1.43.

Hedge Funds Weigh In On Tharimmune

Several institutional investors and hedge funds have recently made changes to their positions in the company. Drucker Wealth 3.0 LLC bought a new stake in shares of Tharimmune in the 3rd quarter valued at $29,000. Essex LLC acquired a new position in Tharimmune in the fourth quarter valued at about $31,000. XTX Topco Ltd bought a new stake in shares of Tharimmune in the second quarter worth about $25,000. State Street Corp raised its position in shares of Tharimmune by 109.0% during the fourth quarter. State Street Corp now owns 36,621 shares of the company’s stock worth $111,000 after purchasing an additional 19,100 shares during the period. Finally, Franklin Resources Inc. acquired a new stake in shares of Tharimmune during the second quarter worth about $88,000. Institutional investors and hedge funds own 1.16% of the company’s stock.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc for the development of proprietary targeted biologics; and Washington University in St.